Tanguy Y. Seiwert
0000-0001-7919-8272
Publication & Citation Trends
Most Cited Works
Publications
382 total
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cited by 2,298
OpenAlex
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 PDF
Cited by 449
OpenAlex
Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy PDF
Cited by 307
OpenAlex
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
Cited by 648
OpenAlex
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Cited by 1,723
OpenAlex
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort PDF
Cited by 851
OpenAlex
Research Topics
Head and Neck Cancer Studies
(168)
Cancer Immunotherapy and Biomarkers
(132)
Lung Cancer Treatments and Mutations
(72)
Cancer Genomics and Diagnostics
(37)
Lung Cancer Research Studies
(31)
Frequent Co-Authors
Affiliations
Broad Institute
University of Maryland, Baltimore
Fox Chase Cancer Center
Roswell Park Comprehensive Cancer Center
Bloomberg (United States)